CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 11 at 8:30 a.m. PT.

A live audio webcast of the presentation and breakout question and answer session will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. Seres’ clinical candidate SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate Ulcerative Colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection. For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180104005392/en/

IR or PR Contact:

Seres Therapeutics

Carlo Tanzi, Ph.D., 617-203-3467

Head of Investor Relations and Corporate Communications

[email protected]

Source: Seres Therapeutics, Inc.

Press Releases